Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 5
Submit an article Journal homepage
2,054
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany

Yiling Jiang Amaris, 1 Water Lane, London NW1 8NZ, UK; Amaris, 1 Water Lane, London NW1 8NZ, UK. [email protected]
,
Aline Gauthier Amaris, 1 Water Lane, London NW1 8NZ, UK
,
Lieven Annemans Ghent Univiersity, De Pintelaan 185, 9000 Ghent, Belgium; Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium
,
Mark van der Linden National Reference Center for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
,
Laurence Nicolas-Spony Sanofi Pasteur MSD, 8, rue Jonas Salk, 69367 Lyon CEDEX 07, France
&
Xavier Bresse Sanofi Pasteur MSD, 8, rue Jonas Salk, 69367 Lyon CEDEX 07, France
Pages 645-660 | Published online: 09 Jan 2014

References

  • Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin. Respir. Crit. Care Med. 30(2), 189–209 (2009).
  • Prato R, Tafuri S, Fortunato F, Martinelli D. Why it is still important that countries know the burden of pneumococcal disease. Hum. Vaccin. 6(11), 918–921 (2010).
  • Fedson DS. Pneumococcal vaccination for older adults: the first 20 years. Drugs Aging 15(Suppl. 1), 21–30 (1999).
  • 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol. Rec. 83(42), 373–384 (2008).
  • Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur. J. Pediatr. 161(4), 188–195 (2002).
  • Hülsse C, Littmann M, Fiedler K, Kaltofen U, Hundt C. Epidemiologic and serologic studies of pneumococcal infections with reference to the new STIKO recommendations. Gesundheitswesen 61(8-9), 393–397 (1999).
  • Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Wkly Epidemiol. Rec. 82(12), 93–104 (2007).
  • Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children – Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep. 59(9), 258–261 (2010).
  • Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59(RR-11), 1–18 (2010).
  • Mitteilung der Ständigen Impfkommission am Robert Koch-Institut: Neuerungen in den aktuellen Empfehlungen der Ständigen Impfkommission (STIKO) am RKI vom Juli 2006. Epid. Bull. 32, 271–276 (2006).
  • Sanofi Pasteur MSD data on file (2011).
  • Scott DA, Komjathy SF, Hu BT et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25(33), 6164–6166 (2007).
  • Baxendale HE, Keating SM, Johnson M, Southern J, Miller E, Goldblatt D. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine 28(30), 4763–4770 (2010).
  • Ridda I, Macintyre CR, Lindley R et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 27(10), 1628–1636 (2009).
  • Miernyk KM, Butler JC, Bulkow LR et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55–70 years of age. Clin. Infect. Dis. 49(2), 241–248 (2009).
  • Baxendale HE, Johnson M, Keating SM et al. Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. Vaccine 28(42), 6915–6922 (2010).
  • Scott D, Ruckle J, Dar M, Baker S, Kondoh H, Lockhart S. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr. Int. 50(3), 295–299 (2008).
  • Dransfield MT, Nahm MH, Han MK et al. COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180(6), 499–505 (2009).
  • Goldblatt D, Southern J, Andrews N et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin. Infect. Dis. 49(9), 1318–1325 (2009).
  • de Roux A, Schmöle-Thoma B, Schmöele-Thoma B et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin. Infect. Dis. 46(7), 1015–1023 (2008).
  • Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J. Infect. Dis. 198(7), 1019–1027 (2008).
  • Fedson DS, Nicolas-Spony L, Klemets P et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev. Vaccines 10(8), 1143–1167 (2011).
  • Varon E. Epidemiology of acute bacterial meningitis in adult patients in France. Med. Mal. Infect. 39(7-8), 432–444 (2009).
  • Trotter CL, Waight P, Andrews NJ et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006. J. Infect. 60(3), 200–208 (2010).
  • Imöhl M, Reinert RR, van der Linden M. Temporal variations among invasive pneumococcal disease serotypes in children and adults in Germany (1992–2008). Int. J. Microbiol. 2010, 874189 (2010).
  • van der Linden M, Imohl M. R2762 Serotype distribution among bacteraemic pneumococcal pneumonia in adults in Germany. Clin. Microbiol. Infect. 17(S4), S832 (2011).
  • Bekanntmachungen des Bundesgesundheitsamtes. Bundesgesundhbl. 25(5), 170–171 (1982).
  • Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: März 1998. Epid. Bull. 15, 101–114 (1998).
  • Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 1, CD000422 (2008).
  • Rodriguez-Barradas MC, Goulet J, Brown S et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin. Infect. Dis. 46(7), 1093–1100 (2008).
  • Musher DM, Manof SB, Liss C et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J. Infect. Dis. 201(4), 516–524 (2010).
  • Hammitt LL, Bulkow LR, Singleton RJ et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 29(12), 2287–2295 (2011).
  • Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270(15), 1826–1831 (1993).
  • Smith KJ, Zimmerman RK, Lin CJ et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost–effectiveness analysis. Vaccine 26(11), 1420–1431 (2008).
  • Evers SM, Ament AJ, Colombo GL et al. Cost–effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur. J. Clin. Microbiol. Infect. Dis. 26(8), 531–540 (2007).
  • Ament A, Baltussen R, Duru G et al. Cost–effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin. Infect. Dis. 31(2), 444–450 (2000).
  • Smith KJ, Lee BY, Nowalk MP, Raymund M, Zimmerman RK. Cost–effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine 28(48), 7620–7625 (2010).
  • Kawakami K, Ohkusa Y, Kuroki R et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 28(43), 7063–7069 (2010).
  • Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost–effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 27(36), 4891–4904 (2009).
  • Akin L, Kaya M, Altinel S, Durand L. Cost of pneumococcal infections and cost–effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey. Hum. Vaccin. 7(4), 441–450 (2011).
  • Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost–effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann. Intern. Med. 138(12), 960–968 (2003).
  • Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective. Clin. Infect. Dis. 33(12), 2078–2079 (2001).
  • European Centre for Disease Prevention and Control. Annual Epidemiological Report on Communicable Diseases in Europe 2010. ECDC, Stockholm, Sweden 2010.
  • Pilishvili T, Lexau C, Farley MM et al. Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201(1), 32–41 (2010).
  • Ardanuy C, Domenech A, Rolo D et al. Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993-2008). J. Antimicrob. Chemother. 65(4), 634–643 (2010).
  • Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect. Dis. 11(10), 760–768 (2011).
  • Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol. Rec. 85(43), 434–436 (2010).
  • Hanage WP, Finkelstein JA, Huang SS et al. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2(2), 80–84 (2010).
  • Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev. Vaccines 8(10), 1351–1364 (2009).
  • Hanage WP. Serotype-specific problems associated with pneumococcal conjugate vaccination. Future Microbiol. 3(1), 23–30 (2008).
  • Reinert RR, Haupts S, van der Linden M et al. Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001–2003. Clin. Microbiol. Infect. 11(12), 985–991 (2005).
  • Dowell SF, Whitney CG, Wright C, Rose CE Jr, Schuchat A. Seasonal patterns of invasive pneumococcal disease. Emerging Infect. Dis. 9(5), 573–579 (2003).
  • Weinstein MC, O’Brien B, Hornberger J et al. ISPOR Task Force on Good Research Practices–Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 6(1), 9–17 (2003).
  • Kyaw MH, Rose CE Jr, Fry AM et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J. Infect. Dis. 192(3), 377–386 (2005).
  • Ryan J, Zoellner Y, Gradl B, Palache B, Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 24(47-48), 6812–6822 (2006).
  • Jansen AG, Rodenburg GD, de Greeff SC et al. Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine 27(17), 2394–2401 (2009).
  • Harboe ZB, Thomsen RW, Riis A et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 6(5), e1000081 (2009).
  • Ewig S, Birkner N, Strauss R et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 64(12), 1062–1069 (2009).
  • Welte T, Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin. Respir. Crit. Care Med. 30(2), 127–135 (2009).
  • Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect. Dis. 10(5), 317–328 (2010).
  • Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J. Infect. 61(2), 114–124 (2010).
  • des Portes V. Long-term follow-up of bacterial meningitis - sequels in children and adults: incidence, type, and assessment issues. Med. Mal. Infect. 39(7-8), 572–580 (2009).
  • Vila-Córcoles A, Ochoa-Gondar O, Hospital I et al. EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin. Infect. Dis. 43(7), 860–868 (2006).
  • Middleton DB, Lin CJ, Smith KJ et al. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. Infect. Control Hosp. Epidemiol. 29(5), 385–394 (2008).
  • Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325(21), 1453–1460 (1991).
  • Mitteilung der Ständigen Impfkommission am Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2011. Epid. Bull. 30, 276–294 (2011).
  • Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297(16), 1784–1792 (2007).
  • Manoff SB, Liss C, Caulfield MJ et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years. J. Infect. Dis. 201(4), 525–533 (2010).
  • Claes C, Reinert RR, von der Schulenburg JM. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur. J. Health Econ. 10(1), 25–38 (2009).
  • Schulze-Gattermann H, Illg A, Schoenermark M, Lenarz T, Lesinski-Schiedat A. Cost–benefit analysis of pediatric cochlear implantation: German experience. Otol. Neurotol. 23(5), 674–681 (2002).
  • Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost–effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin. Ther. 32(8), 1517–1532 (2010).
  • De Wals P, Petit G, Erickson LJ et al. Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada. Vaccine 21(25-26), 3757–3764 (2003).
  • Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost–effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Eff. Resour. Alloc. 7, 9 (2009).
  • Neilson AR, Sieper J, Deeg M. Cost–effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. Rheumatology (Oxford) 49(11), 2122–2134 (2010).
  • Aballéa S, Chancellor J, Martin M et al. The cost–effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health 10(2), 98–116 (2007).
  • Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford University Press, Oxford, UK (2006).
  • Vila-Corcoles A, Salsench E, Rodriguez-Blanco T et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case–control study. Vaccine 27(10), 1504–1510 (2009).
  • Maruyama T, Taguchi O, Niederman MS et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 340, c1004 (2010).
  • Sisk JE, Moskowitz AJ, Whang W et al. Cost–effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 278(16), 1333–1339 (1997).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.